| palonosetron intravenous / Generic mfg. |
2006-000755-18: Estudio Fase IV, Nacional, Multicéntrico, competitivo, aleatorizado, doble ciego, controlado de grupos paralelos, para determinar la seguridad, tolerabilidad, y eficacia de aprepitant, más palonosetrón frente a granisetrón en la prevención de las náuseas y la emesis inducidas por quimioterapia en pacientes tratados con trasplante de progenitores hematopoyéticos. |
|
|
| Ongoing | 4 | 196 | Europe | EMEND, Aloxi, Kytril, EMEND, Aloxi, Kytril | Fundación PETHEMA | náuseas y vómitos producidos en pacientes tratados con quimioterapia previa al transplante de progenitores hematopoyéticos | | | | |
2005-002641-39: Open-Label Pilot Study to Evaluate the Efficacy of Palonosetron Associated with Aprepitant (Emend) and Dexamethasone in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (HEC) |
|
|
| Ongoing | 4 | 60 | Europe | Palonosetron, Fortecortin, Aloxi®, Emend, Fortecortin, Aloxi®, Emend, Fortecortin | Helsinn Healthcare SA | This is a Phase 4, open-label, pilot study to evaluate the Efficacy of Plaonosetron associated with Aprepitant (Emend) and Dexamethasone in preventing nausea and vomitting in chemotherapy-naïve patients, 18 years or older receiving a Highly Emetogenic Chemotherapy (HEC) regimen containing cisplatin ≥70 mg/m2. | | | | |
2006-005803-33: ÉTUDE PILOTE OBSERVATIONNELLE CHEZ DES PATIENTES SOUFFRANT D’UN CANCER DU SEIN ET RECEVANT UNE CHIMIOTHÉRAPIE ÉMÉTISANTE TRAITÉES PAR UNE DOSE UNIQUE DE ALOXI® (PALONOSÉTRON) 0,25 MG ASSOCIÉE À UNE CORTICOTHÉRAPIE |
|
|
| Ongoing | 4 | 150 | Europe | ALOXI, SOLU-MEDROL, ALOXI, SOLU-MEDROL | THERABEL LUCIEN PHARMA | The prevention of acute or delayed Chemotherapy-Induced Nausea and Vomiting (CINV) by the combination of palonosetron 250 microgrammes and methylprednisolone 80 mg in patients receiving a first administration of a first line of emetogenic chemotherapy to treat their non metastatic breast cancer. | | | | |
2015-003956-32: Can the drug palonosetron reduce the risk for postdischarge nausea and vomiting the days after ambulatory surgery? Kan palonosetron minska risken för illamående och kräkning efter hemgång hos dagkirurgiska patienter? |
|
|
| Ongoing | 4 | 700 | Europe | Aloxi, Injection, ALOXI | Umeå University, Västernorrland County Council, Umeå University | Nausea and vomiting in the home (after discharge) after day-case surgery under general anesthesia- Illamående och kräkning efter hemgång vid dagkirurgi., Nausea and vomiting in the home (after discharge) after day-case surgery under general anesthesia- Illamående och kräkning efter hemgång (i hemmet) vid dagkirurgi., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | | | | |
NCT04576390: Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP |
|
|
| Not yet recruiting | 4 | 90 | NA | Ondansetron 4 mg, Zofran, Palonosetron 75 mcg, Aloxi | Theodor Bilharz Research Institute, Cairo University | Antiemetic, Postoperative Nausea and Vomiting | 04/21 | 05/21 | | |
2011-004446-17: A clinical trial to investigate metoclopramide, dexamethasone or Aloxi for the prevention of nausea and vomiting occuring more than 24 hours after chemotherapy administration: the MEDEA trial |
|
|
| Ongoing | 3 | 450 | Europe | dexamethasone, METOCLOPRAMIDE HYDROCHLORIDE-0-WATER, metoclopramide-hydrochloride, dexamethasone PCH, primperan, Primperan suppository, Aloxi, dexamethasone PCH, primperan, Primperan suppository, Aloxi | VU University Medical Center Amsterdam, VU University Medical center Amsterdam | Patients with cancer receiving moderately emetogenic non-AC-based chemotherapy | | | | |
A221602, NCT03578081: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy |
|
|
| Completed | 3 | 690 | US, RoW | Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Malignant Neoplasm | 11/21 | 05/23 | | |
NCT04912271: Granisetron Transdermal Patch for Prophylaxis of Delayed CINV |
|
|
| Not yet recruiting | 3 | 140 | NA | Granisetron transdermal patch, sancuso, Palonosetron, Aprepitant, Fosaprepitant, Dexamethasone | Fudan University | Chemotherapy-induced Nausea and Vomiting (CINV) | 06/22 | 12/23 | | |
NCT05199818: Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC |
|
|
| Recruiting | 3 | 328 | US | Palonosetron HCl Buccal Film 0.5 mg, IV Palonosetron 0.25 mg | Xiamen LP Pharmaceutical Co., Ltd | Chemotherapy-induced Nausea and Vomiting | 09/23 | 11/23 | | |
| Active, not recruiting | 3 | 72 | US | Granisetron, Kytril, Ondansetron, Zofran, Palonosetron, Aloxi | University of Colorado, Denver, Memorial Sloan Kettering Cancer Center, Rutgers University, National Institute of General Medical Sciences (NIGMS) | Nephrotoxicity | 09/25 | 12/26 | | |
2006-002935-25: multicenter phase II study to evaluate palonosetron +desametasone in the prevention of nausea and vomiting in patientes resected for colon cancer and treated with moderate emetogenus chemotherapy. |
|
|
| Ongoing | 2 | 81 | Europe | LEDERFOLIN*EV 1FL LIOF 175MG, FLUOROURACILE TEVA*IV FL 5G, ELOXATIN*IV 1FL POLV 100MG, ALOXI*1FL 250MCG 5ML, SOLDESAM*INIET 3F 1ML 4MG, LEDERFOLIN*EV 1FL LIOF 175MG, FLUOROURACILE TEVA*IV FL 5G, ELOXATIN*IV 1FL POLV 100MG, ALOXI*1FL 250MCG 5ML, SOLDESAM*INIET 3F 1ML 4MG | GOIM GRUPPO ONCOLOGICO MERIDIONALE | patientes resected for colon cancer and treated with moderate emetogenus | | | | |
ChiCTR2300075943: Megestrol acetate plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting induced by moderate-emetogenic chemotherapy in patients with gastric cancer:A randomized, multi-center, phase 3 trial |
|
|
| Not yet recruiting | 1 | 326 | | Megestrol acetate 160mg orally once a day d1-3+Palonosetron 0.25mg IV infusion completed within 30 minutes before chemotherapy, d1.; Dexamethasone 10 mg d1,5mg d2,d3 orally once a day + palonosetron 0.25 mg IV infusion completed within 30 minutes before chemotherapy d1. | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Clinical Research Fund in West China Hospital of Sichuan University | gastric cancer, chemotherapy-induced nausea and vomiting | | | | |
